Given the effects of GPR119 in β-cells (34–36), more studies are necessary to understand the effects of GPR119 biased agonism and investigate whether it might be plausible to stimulate the insulin release and treat T2D. The gene discussed is INS; the disease is type 2 diabetes mellitus.